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Tumors whose primary site is challenging to diagnose
represent a considerable proportion of new cancer
cases. We present validation study results for a gene
expression-based diagnostic test (the Pathwork Tis-
sue of Origin Test) that aids in determining the tissue
of origin using formalin-fixed, paraffin-embedded
(FFPE) specimens. Microarray data files were gener-
ated for 462 metastatic, poorly differentiated, or un-
differentiated FFPE tumor specimens, all of which
had a reference diagnosis. The reference diagnoses
were masked, and the microarray data files were an-
alyzed using a 2000-gene classification model. The
algorithm quantifies the similarity between RNA ex-
pression patterns of the study specimens and the 15
tissues on the test panel. Among the 462 specimens,
overall agreement with the reference diagnosis was
89% (95% CI, 85% to 91%). In addition to the positive
test results (ie, rule-ins), an average of 12 tissues for
each specimen could be ruled out with >99% proba-
bility. The large size of this study increases confi-
dence in the test results. A multisite reproducibility
study showed 89.3% concordance between laborato-
ries. The Tissue of Origin Test makes the benefits of
microarray-based gene expression tests for tumor di-
agnosis available for use with the most common type
of histology specimen (ie, FFPE). (J Mol Diagn 2011, 13:
48–56; DOI: 10.1016/j.jmoldx.2010.11.001)
Tumors whose primary site is challenging to diagnose
represent 3% to 5% of all new cancer cases.1 Patholo-
gists and oncologists undertake exhaustive determina-
tion of tissue of origin in clinicopathologically ambiguous
tumor tissues, often at considerable cost. Immunohisto-
chemistry (IHC) panels, serummarkers, imaging tests, and
other assays are used, because most oncology treatments
are predicated on known primary cancers, as are indica-
tions for anticancer drugs, reimbursement policies,2 and
48entry criteria for clinical trials. For most oncologists, the
primary site is the starting point for standard-of-care patient
management. Studies have associated improved survival
with institution of tumor-specific therapy in those cases
where the primary site was eventually identified.3,4 It is this
expectation of improved outcome with tumor-specific ther-
apy that motivates the search for the primary site in clinical
practice today, and the search has recently intensified, with
new targeted drugs introduced as therapy for specific indi-
cated tumor tissue types.2,5 In addition, a definitive primary
site relieves patient anxiety over uncertain diagnosis.
Although IHC staining can often narrow the range of
diagnostic possibilities6–8 or discriminate among two or
three tissue types,9,10 such panels often lack the combi-
nation of range, sensitivity, and specificity needed for
unequivocal identification of the primary site of origin,
particularly if a wide range of possible primary sites must
be considered.7,11–13 Selection and use of IHC stains
also tend to differ from institution to institution. Further-
more, interpretation and reporting of IHC results remain
highly subjective. A recent meta-analysis of four large
studies, in which pathologists were blinded to knowledge
of the primary site and clinical data, showed that IHC
correctly identified the primary site in only 66% (95% CI
60% to 71%) of metastatic cancers.14 In patients who
present initially with a primary cancer of uncertain origin,
a primary site is eventually identified in 30%.6
Recently, gene expression tests have been developed
as an adjunct to morphological evaluation and IHC anal-
ysis in the evaluation of patients with uncertain primary
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microarrays or RT-PCR to quantify mRNA or mi-
croRNA.4,15–27 The microarray-based assays are capable
of measuring the expression levels of thousands of gene
markers, whereas the RT-PCR–based assays focus on a
smaller subset of 10 to 100 gene markers. Although the
design, development, and performance characteristics of
these expression tests vary, overall accuracy in identifying
the source of poorly differentiated lesions from known pri-
mary cancers has been in the range of 75% to 89%.
In the largest study to date, a microarray-based ex-
pression test validated on 547 snap-frozen specimens
had 88% accuracy in identifying the tissue of origin,21
and the assay delivered reproducible results (94% con-
cordance) in different laboratory settings.18 This evi-
dence of robust microarray performance across a wide
range of poorly differentiated tissues is supported by
statistical analyses suggesting that for highly dimensional
cancer classification problems (eg, when choosing a sin-
gle tissue type from more than a dozen possible types),
the optimal number of gene expression markers is1000
genes (Buturovic LJ: On the optimal number of gene
expression markers for tissue of origin cancer diagnos-
tics. Poster presented at: Annual Meeting for the Ameri-
can Association for Cancer Research; September 17–20,
2007; Atlanta, GA; B4).22,28
Although both statistical theory and validation data
support use of microarrays for primary tumor site classi-
fication, array technologies have traditionally required
large amounts of fresh or frozen tissue, which is imprac-
tical for routine clinical use. Until recently, the degraded
RNA typically found in formalin-fixed paraffin-embedded
(FFPE) tissue had been considered unsuitable for mi-
croarray analysis. Nucleic acids are well known to un-
dergo chemical degradation, fragmentation, cross-link-
ing with proteins, and methylation (especially of poly-A
tails) during fixation and storage.29–37
In recent years, however, the assumption that FFPE
specimens cannot provide adequate RNA for meaningful
microarray analysis has been reconsidered.38–40 Several
studies have now documented that microarray tests can
be performed on FFPE specimens, not only for measure-
ment of short noncoding microRNAs,41–43 but also for
simultaneous quantification of the hundreds of thousands
of diverse mRNA transcripts that cumulatively represent
the full picture of genome-wide expression.26,44–49
The Pathwork Tissue of Origin Test (Pathwork Diagnos-
tics, Redwood City, CA) is a microarray-based gene ex-
pression test that compares the RNA profile of a tumor
FFPE specimen to established RNA profiles of 15 known
tissues. The test measures the degree of similarity be-
tween the expression patterns of the tumor and those of
a panel of 15 different tissue types. The tumor tissue
types represented are bladder, breast, colorectal, gas-
tric, hepatocellular, kidney, non–small cell lung, ovarian,
pancreatic, prostate, thyroid carcinomas, melanoma, tes-
ticular germ cell tumor, non-Hodgkin’s lymphoma, and
sarcoma. For each specimen, the test produces 15 sep-
arate Similarity Scores (SS), one for each tissue type on
the panel. A Tissue of Origin Test report with these results
is provided to the oncologist and pathologist, and isintended to be used in the context of the patient’s history
and other test results.
Here we present results from a multicenter clinical
validation study and an interlaboratory reproducibility
study of the Pathwork Tissue of Origin Test for FFPE, a
microarray-based gene expression test cleared by the
Food and Drug Administration that uses a 2000-gene
profile for identifying a tumor’s tissue of origin in FFPE
samples. Although the panel of tumor tissues classified by
this test is the same as the panel for the previously pub-
lished Tissue of Origin Test for frozen specimens,21 the
algorithms used and the processing methods are different,
and therefore it is a distinct test requiring an independent
validation study, as reported here.
Materials and Methods
Overall Study Design
Formalin-fixed, paraffin-embedded, tumor specimens
were analyzed with the Tissue of Origin Test for FFPE
(Figure 1). All sample preparation and microarray testing
was performed at one of four independent processing
laboratories: Affymetrix Clinical Services Laboratory
(West Sacramento, CA), Cogenics (Research Triangle
Park, NC), Expression Analysis (Research Triangle Park,
NC), Pathwork Diagnostics Laboratory (Redwood City,
CA). Affymetrix Clinical Services Laboratory, Expression
Analysis, and Pathwork Diagnostics Laboratory per-
formed experiments for the validation study; intersite
reproducibility was assessed at Expression Analysis,
Pathwork Diagnostics Laboratory, and Cogenics. Labo-
ratories performing the test were blinded to the reference
diagnoses of samples. Microarray data files (CEL files)
were sent to Pathwork Diagnostics for analysis with com-
puter algorithms for data normalization, data verification
(quality control)18 and tissue of origin classification. All
algorithms had been prespecified (ie, locked) before
data analysis. The set of specimens used for clinical
validation was completely independent of the set of spec-
imens that had been used for algorithm training.
Tissue calls issued by the test for 462 evaluable spec-
imens were compared with the known diagnoses for the
specimens. The primary endpoint was overall percent
agreement between expression results and the reference
diagnoses. The average number of tissues that could be
ruled out as a tissue of origin for each specimen was also
calculated. Other endpoints included the yield of total
RNA from FFPE specimens, the impact on test perfor-
mance of specimen biopsy site, status as primary or
metastatic tumor, block age and percent viable tumor,
and the interlaboratory reproducibility of the test as de-
termined by analysis of 60 specimens (4 of each tissue
type) in each of three laboratories.
Development of the Tissue of Origin Test
The Pathwork Tissue of Origin Test for FFPE uses an RNA
expression profile of 2000 gene markers to assess the
similarity of the patient tumor to a panel of 15 known
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one for standardization and one for classification.
Standardization corrects for variations due to differ-
ences in RNA quality, sample storage and preparation,
operators, or microarray procedures.18 The standardiza-
tion algorithm was developed by evaluating5000 tissue
specimens in multiple laboratories to identify a set of
stable probe sets or markers that could be applied to
normalize raw probe-level intensity values across every
array. The specimens spanned a range of tissues. The
data files were derived from fresh-frozen specimens pro-
cessed by 11 laboratories, and consisting of 85% cancer
and 15% normal and adjacent normal tissue samples.
Figure 1. Tissue of Origin Test Workflow. To perform the Tissue of Origin
Test, total RNA from an FFPE specimen is processed to labeled cDNA for
hybridization to the Pathchip microarray. The microarray data file (CEL) is
then transmitted to Pathwork Diagnostics (Redwood City, CA) for analysis. A
Tissue of Origin Test report is produced, with one Similarity Score (SS) for
each of the 15 tissue types as shown here in a sample report for a colorectal
tissue of origin. The sum of the 15 SS values is always 100. A tissue with an
SS value of 5 can be ruled out with 99% likelihood.The data set included publicly available CEL files fromthe International Genomics Consortium’s Expression
Project for Oncology (expO), deposited in the GEO da-
tabase) under the GSE number 2109, and from commer-
cial data sources. The goal was to include files that
spanned an adequate range of laboratories and opera-
tors to ensure that the genes used for standardization
were highly robust.
Standardized expression data are evaluated in the
test’s classification algorithm. which was developed us-
ing a database of 2032 frozen and 104 FFPE specimens,
divided into independent training and test data sets. The
training set data are a combination of public data sets,
commercial data sources, and private correspondence.
The publicly available component has been derived from
GEO (GSE number 2109). All training specimens had
been assigned one of 15 tissue of origin diagnoses ac-
cording to standard clinical and pathological practices.
The test set consisted of the FFPE specimens. Machine
learning techniques guided selection of the 2000-gene
profile and the optimal model needed to classify the
tumor. The model consists of a list of markers and a set of
coefficients. These components are combined to pro-
duce 15 similarity scores, each corresponding to the
probability that the input specimen has a molecular sig-
nature of the corresponding tissue of origin.
FFPE Specimens
Specimens were admitted into the clinical validation
study using the following entry criteria. (i) Samples were
obtained under an institutional review board-approved
procedure. (ii) All human tumor samples were selected
from the 15 tumor tissues included in the Pathwork Tissue
of Origin Test panel. These tissues are: bladder, breast,
colorectal, gastric, testicular germ cell, kidney, hepato-
cellular, and non-small cell lung cancer, as well as non-
Hodgkin’s lymphoma, melanoma, ovarian cancer, pan-
creatic cancer, prostate cancer, thyroid cancer, and
sarcoma. (iii) All samples were selected from the 58 mor-
phologies included in the development of the Pathwork
Tissue of Origin Test. A complete list is provided in Sup-
plemental Table S1 (http://jmd.amjpathol.org). (iv) To ap-
proximate the test’s likely use in clinical practice, the
specimens were all metastases or primaries that were
poorly differentiated or undifferentiated. (v) Specimens
contained enough material for one 10-m-thick curl for
microarray analysis, and one 5-m-thick H&E-stained
section for confirmation of 60% tumor tissue. The curls
were stored at 4°C and protected from light. (vi) All spec-
imens were estimated to contain 60% tumor tissue by
the vendor pathologist. A board-certified Pathwork pa-
thologist reviewed H&E slides to ensure consistency with
the reference diagnoses, verify percent tumor, and note
percent necrosis of all specimens before processing. If
percent tumor was not consistent with the vendor de-
scription, the Pathwork pathologist assessment was used
for this study. If histology was not consistent, the speci-
men was excluded from the study. Tumor is defined as
tumor cells plus stroma. (vii) Clinical information associ-
ated with specimens was requested but not required for
entry. Available clinical information was recorded for age,
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which specimen was obtained (Table 1), tissue dimen-
sions, and date (year) in which specimen was obtained.
The FFPE specimens were obtained from seven differ-
ent human tumor tissue banks. Specimens had been
resected within the past 5 years. The FFPE specimens
used in this study reflected the range of acquisition and
handling standards used by each tissue bank and its
affiliated community, and academic oncology practices.
Specimens had been designated as one of the 58 mor-
phologies consolidated into 15 tissue types covered by
the Tissue of Origin Test, and ranged from 25 to 57
specimens for each tissue. After acquisition, screening,
de-identification, and coding at Pathwork Diagnostics,
specimens were distributed to one of four laboratories for
processing and microarray scanning.
RNA Extraction and Processing
Total RNA was extracted and isolated from each 10-m-
thick FFPE curl per the manufacturer’s instructions for use
of FormaPure for nucleic acid isolation from formalin-fixed
paraffin-embedded tissue (Agencourt; Beckman-Coulter
Genomics, Beverly, MA) and Ambion DNase I RNA-free
kit (Ambion; Life Technologies, Austin, TX). Total RNA
concentration was determined with a spectrophotometer
(NanoDrop, Wilmington, DE). Two-cycle RNA amplifica-
tion was accomplished with the RampUP kit (Genisphere,
Hatfield, PA). Starting material was 30 ng total RNA at a
concentration of 10 ng/L. A minimum of 25 g sense
RNA and a yield of 2.5 g labeled cDNA were required to
proceed to microarray analysis. At all sites, a positive/
negative control was run with every batch of specimens.
In the reproducibility portion of this study, adjacent
10-m-thick curls were obtained from FFPE blocks from
60 specimens. A set of 60 curls was sent to each of three
sites for RNA isolation and processing. This study was
designed to measure overall clinical reproducibility by
including key sources of expected variation, such as
Table 1. Patient Characteristics
Characteristic No.
Total sample size 462
Sex (n  462)
F 257
M 205
Age range (n  459)
10 to 20 3
20 to 30 19
30 to 40 44
40 to 50 79
50 to 60 133
60 to 70 104
70 to 80 63
80 14
Ethnicity (n  385)*
African American 3
Asian/Pacific Islander 68
European origin 314
F, female; M, male.
*As recorded by tissue bank at sample acquisition.variation across a single FFPE tumor specimen block,multiple operators, multiple days, and multiple lots of
reagents.
Specimen Processing
Of 595 specimens from which RNA isolation was at-
tempted, 549 (92%) yielded at least 150 ng. Thirty nano-
grams total RNA is required to perform the Tissue of
Origin Test. Total RNA from 563 samples (30 ng each)
was processed. Of these, 549 (98%) were processed
successfully and were hybridized to Pathchip microar-
rays. Of the 549 specimens, all 549 (100%) met the
minimum cDNA criterion of 2.5 g needed for hybrid-
ization. Of the 549, 462 (84%) passed prespecified mi-
croarray quality control criteria and were used in data
analyses. In all cases at each site, the batch control on
each processing plate gave the correct prediction.
Microarray Analysis
The Tissue of Origin Test used Pathchip microarrays
manufactured by Affymetrix (Affymetrix, Santa Clara,
CA). Following specimen processing, labeled cDNA was
hybridized to the Pathchip microarray. The microarrays
were washed and stained using the GeneChip hybridiza-
tion wash and stain kit in a GeneChip fluidics station
FS450 or FS450Dx. All arrays were scanned with an Af-
fymetrix GeneChip scanner 3000 or 3000Dx. The result-
ing intensity data (CEL files) were sent to Pathwork Diag-
nostics, where data quality was verified to meet the
prespecified quality control metrics of Overall Signal
10, Percent Present 5, and Regional Discontinuity
0.84. The metrics are calculated as follows. (i) The
Overall Signal value is the mean of the summarized ex-
pression values of all probe sets on the Pathchip microar-
ray; low overall signal (and low Percent Present, de-
scribed below) is likely the result of inadequate
amplification, insufficient quantities of labeled cDNA or
inadequate hybridization time or temperature. (ii) The
Percent Present value is the percentage of probe sets on
the Pathchip microarray that are assigned a Present call
by the Affymetrix MAS 5.0 algorithm, excluding the Af-
fymetrix control probe sets with “AFFX_” as prefix. (iii)
Regional Discontinuity is the probe-level correlation be-
tween the intensity of a probe and the mean intensity of
the two vertically adjacent probes on the chip surface,
computed over all Pathchip probes, and measures any
variation in regional probe intensity that could result from
air pockets or other hybridization problems.
The microarrays that passed the quality metrics were
used to generate the Tissue of Origin Test results, which
were automatically generated by the computer algorithm
without consideration of the reference diagnosis.
Sample Size
The minimum sample size for clinical validation was
found to be at least 351 samples or at least 23 specimens
per tissue source, based on the 85% power to exclude
the null hypothesis that percent agreement is 75% ( 
0.05) if the true percent agreement is at least 81% (cor-
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from feasibility studies). In the clinical validation study,
462 files were analyzed, with 25 to 57 specimens repre-
senting each tissue type.
Data Analysis
The Tissue of Origin Test report was interpreted and
results were analyzed using the following guide to report
interpretation: The SS is a measure of the similarity of the
RNA expression pattern of the specimen to the RNA
expression pattern of the indicated tissue. Similarity
Scores range from 0 (very low similarity) to 100 (very high
similarity) and sum to 100 across all 15 tissues on the panel.
The highest SS indicates the likely tissue of origin, with one
exception: in male patients, a highest SS for ovarian cancer,
followed by a second highest SS for testicular germ cell
cancer, corresponds to testicular germ cell cancer. An SS
of 5 rules out that tissue type as the likely tissue of origin.
In male patients, when testicular germ cell cancer tissue
was the highest SS, the result was in agreement with the
available diagnosis 100% of the time (12/12). There were
nine other cases in males in which ovarian cancer was the
highest SS and testicular germ cell cancer was the second
highest SS; 100% of the cases (9/9) were testicular germ
cell cancer by available diagnosis. Similarity Scores for
ovarian cancer in males and prostate cancer or testicular
germ cell tumor in females have no clinical significance.
Such SS, if they occur, result from RNA expression patterns
that are similar to patterns in the database.
Data analysis for the primary outcome, percent agree-
ment with reference diagnoses, involved dividing the
number of FFPE specimens for which the test result
matches the reference diagnosis by the total number of
FFPE specimens for which a Tissue of Origin Test Report
was generated. The percent agreement and nonagree-
ment were calculated with 95% confidence intervals. The
positive percent agreement was calculated as 100 
TP/POS, where TP is the number of test results that
matched the reference diagnoses for the given tissue of
origin and POS is the total number of positive specimens
Table 2. Tissue of Origin Test Clinical Validation Results
Reference cancer diagnosis Agreement % (ratio)
Bladder 79.3 (23/29)
Breast 96.5 (55/57)
Colorectal 91.7 (33/36)
Gastric 72.0 (18/25)
Hepatocellular 96.0 (24/25)
Kidney 89.3 (25/28)
Melanoma 84.0 (21/25)
Non-Hodgkin’s lymphoma 89.7 (26/29)
Non-small cell lung 85.2 (23/27)
Ovarian 88.9 (40/45)
Pancreas 85.7 (24/28)
Prostate 96.0 (24/25)
Sarcoma 88.9 (24/27)
Testicular germ cell 84.0 (21/25)
Thyroid 90.3 (28/31)
Overall 88.5 (409/462)as per reference diagnosis for the given tissue of origin.The negative percent agreement was calculated as
100  [1  (FP/NEG)], where FP is the number of test
results that are false positive (as per the reference diag-
noses) for the given tissue of origin and NEG is the
number of negative specimens as per the reference di-
agnosis for the given tissue of origin. The diagnostic odds
ratio50 was calculated for each tissue type to provide a
single indicator of test performance in these populations.
Other outcomes of interest (eg, specimens with adequate
total or sense RNA, labeled cDNA, and passing data
verification) were reported as simple percentages. For
the reproducibility study, if the Tissue of Origin result from
one site matched the result from another site, the results
were considered concordant. Overall pairwise concor-
dance is reported. Kappa analysis for intersite agree-
ment51 and Bland-Altman analysis to assess systematic
bias between laboratories52 were also performed.
Results
Agreement with Reference Diagnoses
For the 462 qualified specimens, overall agreement of the
test result with reference diagnoses was 88.5% (95% CI,
85.3% to 91.3%) (Table 2). The positive percent agreement
was 88.5, and the negative percent agreement was 99.1.
When the entire data set of 5732 SS with a value of 5
was analyzed, it was found that any tissue type with an SS
of 5 had a 99.8% probability of not being the Tissue of
Origin. Thus, for each specimen, in addition to the single
positive call, an average of 12 tissues were ruled out (ie, SS
5) with 99.8% accuracy. The diagnostic odds ratio, a
commonly used single measure of test performance, was
100 for all 15 tissues, with a range of 185 (for gastric) to
14,292 (for liver and prostate) indicating that all 15 tests are
highly informative.
The distribution of Tissue of Origin Test results is shown in
Table 3 and indicates the high level of overall agreement of
the test results with the reference diagnoses.
The average highest SS for the 409 specimens whose
95% CI Nonagreement % (ratio) 95% CI
0.3–92.0 20.7 (6/29) 8.0–39.7
7.9–99.6 3.5 (2/57) 0.4–12.1
7.5–98.2 8.3 (3/36) 1.8–22.5
0.6–87.9 28.0 (7/25) 12.1–49.4
9.6–99.9 4.0 (1/25) 0.1–20.4
1.8–97.7 10.7 (3/28) 0.3–28.2
3.9–95.5 16.0 (4/25) 0.5–36.1
2.6–97.8 10.3 (3/29) 2.2–27.4
6.3–95.8 14.8 (4/27) 4.2–33.7
5.9–96.3 11.1 (5/45) 3.7–24.1
7.3–96.0 14.3 (4/28) 4.0–32.7
9.6–99.9 4.0 (1/25) 0.1–20.4
0.8–97.6 11.1 (3/27) 2.4–29.2
3.9–95.5 16.0 (4/25) 4.5–36.1
4.2–98.0 9.7 (3/31) 2.0–25.8
5.3–91.3 11.5 (53/462) 8.7–14.76
8
7
5
7
7
6
7
6
7
6
7
7
6
7calls were in agreement with the reference diagnosis was
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SS of 39.9 for the 53 specimens that were not in agreement.
Analysis of Subgroups
Test performance was good with both metastatic speci-
mens (n  179; 91.1% agreement) and with poorly differ-
entiated to undifferentiated primary tumors (n 283; 86.9%
agreement) (Table 4). For the 179 metastatic specimens,
Tissue of Origin Test results were stratified by biopsy site
(Table 5). The percent agreement in 113 specimens taken
from lymph nodes (92.0%) was similar to that observed in
biopsies from other sites, and no apparent difference in
performance related to biopsy site was seen.
Test performance was consistent at all levels of viable
percent tumor 60%, the prespecified cutoff for speci-
men adequacy. Agreement ratios for positive calls were
91.9% (34/37) in the lowest 60% to 70% viable tumor
range, 85.2% (46/54) in the 70% to 80% range, 90.9%
(100/110) in the 80% to 90% range, and 88.1% (133/151)
in the 90% range. There was no indication of deterio-
rating performance at the lower range of percent tumor in
the specimen.
Test results were stratified by the age of the FFPE block
(Table 6). There was no trend of diminishing performance in
older specimens. Data for FFPE blocks 4 years old were
not sufficient (n  6) to make any conclusions about per-
formance. Test performance was similar at the three test
Table 3. Distribution of Tissue of Origin Test Results by Tumor
Specimen (abbreviation)
No. of
specimens
Distribution
BL BR C
Bladder (BL) 29 23 1
Breast (BR) 57 55
Colorectal (CO) 36
Gastric (GA) 25
Germ Cell (GC) 25 1
Kidney (KI) 28
Hepatocellular (LI) 25
Non-Small Cell Lung (LU) 27
Non-Hodgkin’s Lymphoma (LY) 29
Melanoma (ME) 25
Ovarian (OV) 45 1
Pancreas (PA) 28
Prostate (PR) 25
Sarcoma (SC) 27
Thyroid (TH) 31 1
Total 462 23 59
The confusion matrix highlights, on the diagonal in bold, the high level
off the diagonal identify the test results that do not agree with the referen
Table 4. Tissue of Origin Test Performance According to
Metastatic versus Primary Tumor Status
Tumor type
Agreement %
(ratio)
Nonagreement %
(ratio)
Metastatic 91.1 (163/179) 8.9 (16/179)
Primary 86.9 (246/283) 13.1 (37/283)
Overall 88.5 (409/462) 11.5 (53/462)
95% CI 85.3–91.3 8.7–14.7sites: 92.9% (158/170) overall agreement at Affymetrix Clin-
ical Services Laboratory, 87.8% (164/187) at EA, and 82.9%
(87/105) at Pathwork Diagnostics Laboratory.
Probability of Agreement with Reference
Diagnosis by Highest SS
The probability of agreement between a Tissue of Origin
Test result and the reference diagnosis was increased in
specimens with elevated highest SS (Figure 2). Test re-
ports with elevated highest SS are more common, as
indicated by the higher number of specimens in each bin
at the higher SS. The decline of confidence with decreas-
ing highest SS was modest. At the lowest end of the
range (10 to 20), there were only eight specimens; of
these, seven were nonagreements. Therefore, given the
few available data, we conclude that performance has
not been established for test results where the highest SS
is less than 20.
Table 5. Tissue of Origin Test Performance According to
Biopsy Site of Metastatic Samples
Biopsy site
Agreement %
(ratio)
Nonagreement %
(ratio)
Colorectal 100.0 (5/5) 0.0 (0/5)
Gastric 83.3 (5/6) 16.7 (1/6)
Kidney 100.0 (1/1) 0.0 (0/1)
Liver 100.0 (9/9) 0.0 (0/9)
Lung 60.0 (3/5) 40.0 (2/5)
Lymph Node 92.0 (104/113) 8.0 (9/113)
Ovary 100.0 (6/6) 0.0 (0/6)
Soft Tissue 86.7 (13/15) 13.3 (2/15)
Other 89.5 (17/19) 10.5 (2/19)
Overall* 91.1 (163/179) 8.9 (16/179)
sue of Origin Test results result across the 15 tissues on the
Tissue of Origin Test panel
A GC KI LI LU LY ME OV PA PR SC TH
4
1 1 1
8 1 1
21 2
25 3
24 1
1 23 1 1
2 26 1
2 21 2
1 40 2 1
1 24 1
1 24
1 1 24
2 28
4 21 27 24 23 28 21 45 29 24 40 28
ll agreement of the test results with the reference diagnoses. The results
nosis.Type
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2
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1
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2
1
46 2*Metastatic tumors only.
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Laboratories Processing Replicate Specimens
The reproducibility of the test was established in a study
performed at three laboratories. Replicate 10-m-thick curls
were sent to each laboratory and processed to yield 162
Tissue of Origin Test reports. This provided 149 qualified
paired results. Overall concordance between paired results
in the three laboratories was 89.3% (133/149). For each
specimen, the 15 SS produced by each test are considered
the primary diagnostic. The SS for the three laboratory pairs
were evaluated using linear regression and correlation anal-
ysis. Correlation coefficients (r) ranged from 0.92 to 0.93,
and slopes from 0.93 to 0.96, establishing that the test is
highly reproducible. Kappa analysis of intersite agreement
ranged from 0.85 to 0.92. Bland-Altman analysis was per-
formed to assess systematic bias between laboratories that
could adversely affect test results. No evidence of systemic
bias among the three sites was found, in that fewer than
10% of specimens were outside the 95% limit of agreement.
Discussion
The use of RNA expression patterns to determine the
tissue of origin of clinical specimens is a long-awaited
application of molecular biology to an important clinical
problem. Until recently, such application has been de-
layed by the difficulties in obtaining accurate and useful
gene expression measurements from the most commonly
available pathology specimens, which are formalin-fixed
and paraffin-embedded. In a recent article,48 it is stated
that “only a quarter of unselected FFPE samples aged
2–8 years provided RNA of sufficient quality for success-
ful expression analysis,” using microarrays. We describe
methods that allow almost 80% of such formalin-fixed
samples to provide high-quality microarray data. With the
availability of methods for the reproducible extraction and
amplification of FFPE-derived RNA, these routine clinical
specimens have become available for analysis of RNA
expression. This, combined with the ability to measure
the levels of thousands of different RNA sequences using
microarray technology, makes gene expression a power-
ful new tool in oncology diagnostics.
Here we have described such a diagnostic test for the
classification of primary site of tumors in FFPE specimens
derived from metastatic or poorly differentiated tumor
Table 6. Tissue of Origin Test Performance Stratified by Age of
FFPE Specimens
Specimen, year
Agreement %
(ratio)
Nonagreement %
(ratio)
Before 2005 83.3 (5/6) 16.7 (1/6)
2005 86.2 (94/109) 13.8 (15/109)
2006 92.1 (82/89) 7.9 (7/89)
2007 89.9 (134/149) 10.1 (15/149)
2008 86.7 (85/98) 13.3 (13/98)
2009 81.8 (9/11) 18.2 (2/11)
Overall 88.5 (409/462) 11.5 (53/462)
95% CI 85.3–91.3 8.7–14.7specimens. In a blinded, multisite study of 462 FFPEspecimens, the overall agreement of test results with
reference diagnoses was 88.5%. Performance was high
for both metastatic and poorly differentiated primary tu-
mor specimens, showing 91% and 87% agreement, re-
spectively. In contrast, a recent meta-analysis showed
that IHC correctly identified the primary site in only 66%
(95% CI, 60% to 71%) of metastatic cancers, in four large
studies in which pathologists were similarly blinded to
knowledge of the primary site and clinical data.14
This is, to our knowledge, the largest and most rigor-
ously conducted validation of a gene expression–based
test for identifying a tumor’s primary site using formalin-
fixed paraffin-embedded specimens. The large number
of specimens analyzed, with at least 25 specimens per
tissue type, allows confidence in the overall accuracy
results for both rule-in and rule-out of the tissue of origin.
The distribution of specimens validated test performance
for each of the fifteen cancer tissue types.
In addition to issuing a single positive call for each of the
462 FFPE specimens, the Tissue of Origin Test also pro-
duced an average of 12 high-probability negative calls (SS
5) for every specimen. The ability to rule out a dozen
possible tissues of origin in an uncertain tumor has substan-
tial clinical value for pathologists and oncologists.
The agreement rate seen in this study is the highest
reported for an expression-based tissue of origin
test.15,17,20–25 Although other tissue of origin assays have
claimed overall accuracies of approximately 75% to 90%,
the results of each study need to be evaluated carefully
before making comparisons. For example, many classifiers
lose significant accuracy when assessing poorly differenti-
ated or metastatic tissues20,22,26 or a particular tissue
Figure 2. Probability of agreement with reference diagnosis for Tissue of
Origin Test Similarity Score. The x axis indicates the highest SS of a Tissue of
Origin Test report for the 462 specimens, in 10 equal bins from 0 to 100. The
y axis indicates percent probability that the test result in the corresponding
bin of a Tissue of Origin Test report is in agreement with the reference
diagnosis. The probabilities are estimated for SS bins of width 10. Thus, each
bar represents the aggregate probability for the corresponding bin. Error bars
indicate the 95% confidence intervals of the percent probability estimate. The
number of specimens in the bin, used to calculate the probability, is indicated
above each error bar. For example, a report with a highest SS of 75 indicates
actual tissue of origin of the specimen under test approximately 90% of the
time. Note that Tissue of Origin Test results with highest SS of 20 are rare.
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each study also need to be considered, such as sample
size andmethod of reporting accuracy. Such criteria should
be used to assess the validity of performance claims.
By demonstrating that microarray analysis can be per-
formed on FFPE specimens, this study has removed a
major limitation on use of the optimal expression platform
for tissue of origin classification. Microarray analysis of
typical FFPE specimens is feasible, and can provide re-
sults that are accurate and reproducible.
Given the performance documented in this study, the
Tissue of Origin Test appears suitable for use in clinical
settings, especially in the light of the small amounts of ma-
terial required. As little as 30 ng total RNA is sufficient to
perform the test. Appropriate use of this expression test
may eliminate unnecessary diagnostic tests, allow selection
of more targeted therapy, speed enrollment in appropriate
clinical trials, and avoid patient exposures to costly, ineffec-
tive, or potentially toxic treatments. Identification of a tumor’s
primary site with gene expression testing has already been
successfully used as a guide to tumor-specific therapy in a
limited number of cases.4,48,54 The principal goal driving
pathologists’ use of IHC panels and other tests remains
identification of primary cancer site. The present study dem-
onstrated that microarray-based gene expression testing
can further refine this search. As newer targeted therapies
are introduced, the value in improved tissue of origin clas-
sification will only increase.2,5 A recent study with frozen
specimens has shown the utility of the Tissue of Origin Test
in identifying the tissue of origin in tumor specimens from 21
patients with a diagnosis of carcinoma of unknown
primary.55
In summary, this study showed that routine FFPE spec-
imens can be reliably processed to yield high-quality
gene expression microarray data files. The Tissue of Or-
igin Test shows a high degree of agreement with the
reference diagnosis for approximately 9 of every 10
specimens. Tissues on the panel with SS results of 5
can be ruled out as the primary site with99% likelihood.
A multisite interlaboratory study has shown that the Tis-
sue of Origin Test results are highly reproducible, with
89.3% concordance between laboratories. The ability to
obtain high-quality, whole-genome gene expression data
from routine clinical specimens and to convert these data
into accurate and reproducible results, indicating the
likely primary site of a malignancy, will be highly useful as
an aid in the diagnosis of human malignancies. As a
diagnostic test cleared by the U.S. Food and Drug Ad-
ministration that has been rigorously validated and pro-
vides objective information, the Tissue of Origin Test can
assist pathologists and oncologists in determining the
primary sites of tumors, and may thereby help guide
more targeted and less toxic therapy.
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